Clinical Oncology Next Generation Sequencing (NGS) Market Key Findings by 2031
MARKET OVERVIEW
Next-generation sequencing is a technique for sequencing DNA or RNA that enables many reactions to be carried out simultaneously. NGS has transformed cancer genetics in recent years by providing researchers with access to genomic and transcriptomic data. In most of the developed nations the next generation sequencing method is used to develop cancer treatments through novel therapies.
MARKET SCOPE
The "Global Clinical Oncology Next Generation Sequencing (NGS) Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the clinical oncology next generation sequencing (NGS) market with detailed market segmentation by technology, workflow, application and end user. The report provides key statistics on the market status of the leading clinical oncology next generation sequencing (NGS) market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
MARKET DYNAMICS
Drivers:
Restraints:
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The clinical oncology next generation sequencing (NGS) market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the clinical oncology next generation sequencing (NGS) market in these regions.
IMPACT OF COVID-19 ON CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
Speak to Analyst
MARKET PLAYERS
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The clinical oncology next generation sequencing (NGS) market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the clinical oncology next generation sequencing (NGS) market in these regions.
IMPACT OF COVID-19 ON CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
MARKET PLAYERS
The report covers key developments in the clinical oncology next generation sequencing (NGS) market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from clinical oncology next generation sequencing (NGS) market are anticipated to lucrative growth opportunities in the future with the rising demand for clinical oncology next generation sequencing (NGS) in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the clinical oncology next generation sequencing (NGS) market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
Next-generation sequencing is a technique for sequencing DNA or RNA that enables many reactions to be carried out simultaneously. NGS has transformed cancer genetics in recent years by providing researchers with access to genomic and transcriptomic data. In most of the developed nations the next generation sequencing method is used to develop cancer treatments through novel therapies.
MARKET SCOPE
The "Global Clinical Oncology Next Generation Sequencing (NGS) Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the clinical oncology next generation sequencing (NGS) market with detailed market segmentation by technology, workflow, application and end user. The report provides key statistics on the market status of the leading clinical oncology next generation sequencing (NGS) market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
- Based on technology the market is segmented as, whole exome sequencing, whole genome sequencing and targeted sequencing & resequencing.
- Based on workflow the market is segmented as, NGS data analysis, NGS pre-sequencing and NGS sequencing.
- Based on application the market is segmented as, companion diagnostics, screening and other applications.
- Based on end user the market is segmented as, hospitals & clinics and laboratories.
MARKET DYNAMICS
Drivers:
- Increasing prevalence of cancer along with technological advancement in the field of next generation sequencing.
- Increasing significance of next generation sequencing in cancer research.
- Decling cost of genome sequencing is also expected to fuel the market growth.
Restraints:
- However, dearth of skilled professionals, high cost associated with the study along with legal limitations associated with NGS are likely to restrain market growth.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The clinical oncology next generation sequencing (NGS) market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the clinical oncology next generation sequencing (NGS) market in these regions.
IMPACT OF COVID-19 ON CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The clinical oncology next generation sequencing (NGS) market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the clinical oncology next generation sequencing (NGS) market in these regions.
IMPACT OF COVID-19 ON CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
MARKET PLAYERS
The report covers key developments in the clinical oncology next generation sequencing (NGS) market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from clinical oncology next generation sequencing (NGS) market are anticipated to lucrative growth opportunities in the future with the rising demand for clinical oncology next generation sequencing (NGS) in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the clinical oncology next generation sequencing (NGS) market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- Agilent Technologies, Inc.
- Caris Life Sciences
- F. Hoffmann-La Roche Ltd
- FOUNDATION MEDICINE, INC.
- Illumina, Inc.
- Myriad Genetics, Inc.
- Oxford Nanopore Technologies
- PerkinElmer Inc
- QIAGEN
- Thermo Fisher Scientific Inc.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Clinical Oncology Next Generation Sequencing (NGS) Market - By Technology
1.3.2 Clinical Oncology Next Generation Sequencing (NGS) Market - By Workflow
1.3.3 Clinical Oncology Next Generation Sequencing (NGS) Market - By Application
1.3.4 Clinical Oncology Next Generation Sequencing (NGS) Market - By End User
1.3.5 Clinical Oncology Next Generation Sequencing (NGS) Market - By Region
1.3.5.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS
5. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - GLOBAL MARKET ANALYSIS
6.1. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) - GLOBAL MARKET OVERVIEW
6.2. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - REVENUE AND FORECASTS TO 2028 - TECHNOLOGY
7.1. OVERVIEW
7.2. TECHNOLOGY MARKET FORECASTS AND ANALYSIS
7.3. WHOLE EXOME SEQUENCING
7.3.1. Overview
7.3.2. Whole Exome Sequencing Market Forecast and Analysis
7.4. WHOLE GENOME SEQUENCING
7.4.1. Overview
7.4.2. Whole Genome Sequencing Market Forecast and Analysis
7.5. TARGETED SEQUENCING AND RESEQUENCING
7.5.1. Overview
7.5.2. Targeted Sequencing and Resequencing Market Forecast and Analysis
8. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - REVENUE AND FORECASTS TO 2028 - WORKFLOW
8.1. OVERVIEW
8.2. WORKFLOW MARKET FORECASTS AND ANALYSIS
8.3. NGS DATA ANALYSIS
8.3.1. Overview
8.3.2. NGS Data Analysis Market Forecast and Analysis
8.4. NGS PRE-SEQUENCING
8.4.1. Overview
8.4.2. NGS Pre-Sequencing Market Forecast and Analysis
8.5. NGS SEQUENCING
8.5.1. Overview
8.5.2. NGS Sequencing Market Forecast and Analysis
9. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
9.1. OVERVIEW
9.2. APPLICATION MARKET FORECASTS AND ANALYSIS
9.3. COMPANION DIAGNOSTICS
9.3.1. Overview
9.3.2. Companion Diagnostics Market Forecast and Analysis
9.4. SCREENING
9.4.1. Overview
9.4.2. Screening Market Forecast and Analysis
9.4.3. Inherited Cancer Market
9.4.3.1. Overview
9.4.3.2. Inherited Cancer Market Forecast and Analysis
9.4.4. Sporadic Cancer Market
9.4.4.1. Overview
9.4.4.2. Sporadic Cancer Market Forecast and Analysis
9.5. OTHER APPLICATIONS
9.5.1. Overview
9.5.2. Other Applications Market Forecast and Analysis
10. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - REVENUE AND FORECASTS TO 2028 - END USER
10.1. OVERVIEW
10.2. END USER MARKET FORECASTS AND ANALYSIS
10.3. HOSPITALS AND CLINICS
10.3.1. Overview
10.3.2. Hospitals and Clinics Market Forecast and Analysis
10.4. LABORATORIES
10.4.1. Overview
10.4.2. Laboratories Market Forecast and Analysis
11. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
11.1. NORTH AMERICA
11.1.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.1.2 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.1.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.1.4 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.1.5 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.1.6 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.1.7 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.1.7.1 United States Clinical Oncology Next Generation Sequencing (NGS) Market
11.1.7.1.1 United States Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.1.7.1.2 United States Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.1.7.1.3 United States Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.1.7.1.4 United States Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.1.7.2 Canada Clinical Oncology Next Generation Sequencing (NGS) Market
11.1.7.2.1 Canada Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.1.7.2.2 Canada Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.1.7.2.3 Canada Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.1.7.2.4 Canada Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.1.7.3 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market
11.1.7.3.1 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.1.7.3.2 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.1.7.3.3 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.1.7.3.4 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2. EUROPE
11.2.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.2.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.2.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.2.4 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.2.5 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.2.6 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.2.7 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.2.7.1 Germany Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.1.1 Germany Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.1.2 Germany Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.1.3 Germany Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.1.4 Germany Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.2 France Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.2.1 France Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.2.2 France Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.2.3 France Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.2.4 France Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.3 Italy Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.3.1 Italy Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.3.2 Italy Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.3.3 Italy Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.3.4 Italy Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.4 Spain Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.4.1 Spain Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.4.2 Spain Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.4.3 Spain Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.4.4 Spain Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.5 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.5.1 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.5.2 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.5.3 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.5.4 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.6 Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.6.1 Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.6.2 Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.6.3 Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.6.4 Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3. ASIA-PACIFIC
11.3.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.3.2 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.3.3 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.3.4 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.3.5 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.3.6 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.3.7 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.3.7.1 Australia Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.1.1 Australia Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.1.2 Australia Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.1.3 Australia Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.1.4 Australia Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.2 China Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.2.1 China Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.2.2 China Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.2.3 China Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.2.4 China Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.3 India Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.3.1 India Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.3.2 India Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.3.3 India Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.3.4 India Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.4 Japan Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.4.1 Japan Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.4.2 Japan Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.4.3 Japan Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.4.4 Japan Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.5 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.5.1 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.5.2 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.5.3 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.5.4 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.6 Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.6.1 Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.6.2 Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.6.3 Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.6.4 Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.4. MIDDLE EAST AND AFRICA
11.4.1 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.4.2 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.4.3 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.4.4 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.4.5 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.4.6 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.4.7 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.4.7.1 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market
11.4.7.1.1 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.4.7.1.2 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.4.7.1.3 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.4.7.1.4 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.4.7.2 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market
11.4.7.2.1 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.4.7.2.2 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.4.7.2.3 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.4.7.2.4 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.4.7.3 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market
11.4.7.3.1 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.4.7.3.2 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.4.7.3.3 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.4.7.3.4 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.4.7.4 Rest of Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market
11.4.7.4.1 Rest of Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.4.7.4.2 Rest of Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.4.7.4.3 Rest of Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.4.7.4.4 Rest of Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.5. SOUTH AND CENTRAL AMERICA
11.5.1 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.5.2 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.5.3 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.5.4 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.5.5 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.5.6 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.5.7 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.5.7.1 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market
11.5.7.1.1 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.5.7.1.2 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.5.7.1.3 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.5.7.1.4 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.5.7.2 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market
11.5.7.2.1 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.5.7.2.2 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.5.7.2.3 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.5.7.2.4 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.5.7.3 Rest of South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market
11.5.7.3.1 Rest of South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.5.7.3.2 Rest of South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.5.7.3.3 Rest of South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.5.7.3.4 Rest of South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market by End User
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET, KEY COMPANY PROFILES
13.1. AGILENT TECHNOLOGIES, INC.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. CARIS LIFE SCIENCES
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. F. HOFFMANN-LA ROCHE LTD
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. FOUNDATION MEDICINE, INC.
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. ILLUMINA, INC.
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. MYRIAD GENETICS, INC.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. OXFORD NANOPORE TECHNOLOGIES
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. PERKINELMER INC
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. QIAGEN
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. THERMO FISHER SCIENTIFIC INC.
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Clinical Oncology Next Generation Sequencing (NGS) Market - By Technology
1.3.2 Clinical Oncology Next Generation Sequencing (NGS) Market - By Workflow
1.3.3 Clinical Oncology Next Generation Sequencing (NGS) Market - By Application
1.3.4 Clinical Oncology Next Generation Sequencing (NGS) Market - By End User
1.3.5 Clinical Oncology Next Generation Sequencing (NGS) Market - By Region
1.3.5.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS
5. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - GLOBAL MARKET ANALYSIS
6.1. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) - GLOBAL MARKET OVERVIEW
6.2. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - REVENUE AND FORECASTS TO 2028 - TECHNOLOGY
7.1. OVERVIEW
7.2. TECHNOLOGY MARKET FORECASTS AND ANALYSIS
7.3. WHOLE EXOME SEQUENCING
7.3.1. Overview
7.3.2. Whole Exome Sequencing Market Forecast and Analysis
7.4. WHOLE GENOME SEQUENCING
7.4.1. Overview
7.4.2. Whole Genome Sequencing Market Forecast and Analysis
7.5. TARGETED SEQUENCING AND RESEQUENCING
7.5.1. Overview
7.5.2. Targeted Sequencing and Resequencing Market Forecast and Analysis
8. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - REVENUE AND FORECASTS TO 2028 - WORKFLOW
8.1. OVERVIEW
8.2. WORKFLOW MARKET FORECASTS AND ANALYSIS
8.3. NGS DATA ANALYSIS
8.3.1. Overview
8.3.2. NGS Data Analysis Market Forecast and Analysis
8.4. NGS PRE-SEQUENCING
8.4.1. Overview
8.4.2. NGS Pre-Sequencing Market Forecast and Analysis
8.5. NGS SEQUENCING
8.5.1. Overview
8.5.2. NGS Sequencing Market Forecast and Analysis
9. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
9.1. OVERVIEW
9.2. APPLICATION MARKET FORECASTS AND ANALYSIS
9.3. COMPANION DIAGNOSTICS
9.3.1. Overview
9.3.2. Companion Diagnostics Market Forecast and Analysis
9.4. SCREENING
9.4.1. Overview
9.4.2. Screening Market Forecast and Analysis
9.4.3. Inherited Cancer Market
9.4.3.1. Overview
9.4.3.2. Inherited Cancer Market Forecast and Analysis
9.4.4. Sporadic Cancer Market
9.4.4.1. Overview
9.4.4.2. Sporadic Cancer Market Forecast and Analysis
9.5. OTHER APPLICATIONS
9.5.1. Overview
9.5.2. Other Applications Market Forecast and Analysis
10. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - REVENUE AND FORECASTS TO 2028 - END USER
10.1. OVERVIEW
10.2. END USER MARKET FORECASTS AND ANALYSIS
10.3. HOSPITALS AND CLINICS
10.3.1. Overview
10.3.2. Hospitals and Clinics Market Forecast and Analysis
10.4. LABORATORIES
10.4.1. Overview
10.4.2. Laboratories Market Forecast and Analysis
11. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
11.1. NORTH AMERICA
11.1.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.1.2 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.1.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.1.4 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.1.5 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.1.6 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.1.7 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.1.7.1 United States Clinical Oncology Next Generation Sequencing (NGS) Market
11.1.7.1.1 United States Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.1.7.1.2 United States Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.1.7.1.3 United States Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.1.7.1.4 United States Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.1.7.2 Canada Clinical Oncology Next Generation Sequencing (NGS) Market
11.1.7.2.1 Canada Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.1.7.2.2 Canada Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.1.7.2.3 Canada Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.1.7.2.4 Canada Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.1.7.3 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market
11.1.7.3.1 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.1.7.3.2 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.1.7.3.3 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.1.7.3.4 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2. EUROPE
11.2.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.2.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.2.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.2.4 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.2.5 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.2.6 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.2.7 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.2.7.1 Germany Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.1.1 Germany Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.1.2 Germany Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.1.3 Germany Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.1.4 Germany Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.2 France Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.2.1 France Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.2.2 France Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.2.3 France Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.2.4 France Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.3 Italy Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.3.1 Italy Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.3.2 Italy Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.3.3 Italy Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.3.4 Italy Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.4 Spain Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.4.1 Spain Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.4.2 Spain Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.4.3 Spain Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.4.4 Spain Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.5 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.5.1 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.5.2 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.5.3 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.5.4 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.6 Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.6.1 Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.6.2 Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.6.3 Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.6.4 Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3. ASIA-PACIFIC
11.3.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.3.2 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.3.3 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.3.4 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.3.5 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.3.6 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.3.7 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.3.7.1 Australia Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.1.1 Australia Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.1.2 Australia Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.1.3 Australia Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.1.4 Australia Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.2 China Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.2.1 China Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.2.2 China Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.2.3 China Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.2.4 China Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.3 India Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.3.1 India Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.3.2 India Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.3.3 India Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.3.4 India Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.4 Japan Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.4.1 Japan Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.4.2 Japan Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.4.3 Japan Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.4.4 Japan Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.5 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.5.1 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.5.2 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.5.3 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.5.4 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.6 Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.6.1 Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.6.2 Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.6.3 Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.6.4 Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.4. MIDDLE EAST AND AFRICA
11.4.1 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.4.2 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.4.3 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.4.4 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.4.5 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.4.6 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.4.7 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.4.7.1 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market
11.4.7.1.1 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.4.7.1.2 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.4.7.1.3 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.4.7.1.4 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.4.7.2 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market
11.4.7.2.1 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.4.7.2.2 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.4.7.2.3 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.4.7.2.4 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.4.7.3 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market
11.4.7.3.1 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.4.7.3.2 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.4.7.3.3 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.4.7.3.4 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.4.7.4 Rest of Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market
11.4.7.4.1 Rest of Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.4.7.4.2 Rest of Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.4.7.4.3 Rest of Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.4.7.4.4 Rest of Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.5. SOUTH AND CENTRAL AMERICA
11.5.1 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.5.2 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.5.3 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.5.4 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.5.5 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.5.6 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.5.7 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.5.7.1 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market
11.5.7.1.1 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.5.7.1.2 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.5.7.1.3 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.5.7.1.4 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.5.7.2 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market
11.5.7.2.1 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.5.7.2.2 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.5.7.2.3 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.5.7.2.4 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.5.7.3 Rest of South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market
11.5.7.3.1 Rest of South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.5.7.3.2 Rest of South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.5.7.3.3 Rest of South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.5.7.3.4 Rest of South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market by End User
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET, KEY COMPANY PROFILES
13.1. AGILENT TECHNOLOGIES, INC.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. CARIS LIFE SCIENCES
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. F. HOFFMANN-LA ROCHE LTD
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. FOUNDATION MEDICINE, INC.
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. ILLUMINA, INC.
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. MYRIAD GENETICS, INC.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. OXFORD NANOPORE TECHNOLOGIES
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. PERKINELMER INC
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. QIAGEN
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. THERMO FISHER SCIENTIFIC INC.
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies
1. Agilent Technologies, Inc.
2. Caris Life Sciences
3. F. Hoffmann-La Roche Ltd
4. FOUNDATION MEDICINE, INC.
5. Illumina, Inc.
6. Myriad Genetics, Inc.
7. Oxford Nanopore Technologies
8. PerkinElmer Inc
9. QIAGEN
10. Thermo Fisher Scientific Inc.
1. Agilent Technologies, Inc.
2. Caris Life Sciences
3. F. Hoffmann-La Roche Ltd
4. FOUNDATION MEDICINE, INC.
5. Illumina, Inc.
6. Myriad Genetics, Inc.
7. Oxford Nanopore Technologies
8. PerkinElmer Inc
9. QIAGEN
10. Thermo Fisher Scientific Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For